Atrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven
efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety …

OBJECTIVE: The embolization of thrombi formed within the atria can occur in any form of
atrial fibrillation (AF), ie, paroxysmal, persistent, or permanent. Although ischemic stroke is …

Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared
non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban …

Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …

New Anticoagulants in Atrial Fibrillation. Atrial fibrillation (AF) is the most common cardiac
rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using …

Atrial fibrillation (AF) is considered the most common sustained cardiac arrhythmia, and it is
associated with a significant risk of adverse events, especially ischemic stroke. Oral …

Atrial fibrillation (AF) is an important cause of ischemic stroke and is the underlying cause
of> 20% of all strokes, with increasing age being a risk factor. Until recently, warfarin was the …

Atrial fibrillation (AF) is a common cardiac arrhythmia, especially in the elderly population. It
is associated with cardioembolic complications, particularly strokes, resulting in severe …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin
among Asians with non-valvular atrial fibrillation (NVAF) remains unclear in the real-world …

Background: Novel oral anticoagulants (NOACs) have shown to be both safe and effective
for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). We …